Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
ANI Pharmaceuticals, Inc. ANIP
$40.60
-$3.09 (-7.62%)
На 18:00, 12 мая 2023
+18.23%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
765327500.00000000
-
week52high
52.23
-
week52low
22.31
-
Revenue
316385000
-
P/E TTM
-13
-
Beta
1.04083000
-
EPS
-3.08000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 12:30
Описание компании
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Raymond James | Outperform | Outperform | 09 авг 2022 г. |
| Raymond James | Outperform | Outperform | 16 мар 2022 г. |
| Truist Securities | Buy | 02 ноя 2021 г. | |
| Raymond James | Outperform | Outperform | 02 ноя 2021 г. |
| Raymond James | Outperform | Outperform | 10 мая 2021 г. |
| HC Wainwright & Co. | Buy | 07 сент 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| MERIDIAN VENTURE PARTNERS II LP | D | 2019259 | 200000 | 01 дек 2022 г. |
| Davis Krista | A | 16433 | 16433 | 12 сент 2022 г. |
| Lalwani Nikhil | D | 281957 | 3646 | 08 сент 2022 г. |
| Marken James G. | D | 117642 | 5172 | 15 авг 2022 г. |
| Marken James G. | D | 122814 | 12894 | 12 авг 2022 г. |
| Cook Meredith | A | 19280 | 19280 | 18 июл 2022 г. |
| Gutwerg Ori | A | 37644 | 6476 | 27 апр 2022 г. |
| Mutz Christopher | A | 40854 | 6476 | 27 апр 2022 г. |
| Marken James G. | A | 135708 | 6644 | 27 апр 2022 г. |
| HAUGHEY THOMAS | A | 40251 | 10049 | 27 апр 2022 г. |
Новостная лента
ANI Pharmaceuticals (ANIP) Beats Q1 Earnings and Revenue Estimates
Zacks Investment Research
08 мая 2023 г. в 09:08
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.17 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to loss of $0.12 per share a year ago.
New Strong Sell Stocks for March 13th
Zacks Investment Research
13 мар 2023 г. в 08:26
ANIP, ARCB and ARCE have been added to the Zacks Rank #5 (Strong Sell) List on March 13, 2023.
ANI Pharmaceuticals (ANIP) Q4 Earnings and Revenues Top Estimates
Zacks Investment Research
09 мар 2023 г. в 09:11
ANI (ANIP) delivered earnings and revenue surprises of 11.76% and 8.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023, at 8:30 a.m. ET
Business Wire
22 февр 2023 г. в 16:05
BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2022 financial results on Thursday, March 9, 2023, prior to market open. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows: Date Thursday, March 9, 2023 Time 8:30 a.m.
2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To Benefit
Seeking Alpha
01 янв 2023 г. в 08:29
Results from three major testosterone trials expected in 2023, including the largest testosterone cardiovascular safety/efficacy trials for men and women. AbbVie led Androgel 1.62% 5,246-participant cardiovascular safety trial is also measuring efficacy for dysthymia, clinical fractures, anemia, and progression from pre-diabetes to diabetes, results could lead to sNDA submissions.